The clinical evaluation of HER-2 status: Which test to use?

Journal of Pathology

Volumn 199, Issue 4, 2003, Pages 411-417

  Bartlett, John ^a   Mallon, Elizabeth ^b   Cooke, Tim ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

Breast carcinoma; Diagnosis; Evaluation; FISH; HER 2; Herceptin; Immunohistochemistry

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; HORMONE DERIVATIVE; MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN TYROSINE KINASE; TRASTUZUMAB;

AUTOMATION; BREAST CANCER; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL PROTOCOL; DIAGNOSTIC ACCURACY; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MEDICAL DECISION MAKING; MEDICAL LITERATURE; ONCOGENE NEU; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; QUALITY CONTROL; REPRODUCIBILITY; REVIEW; SCREENING TEST; STANDARDIZATION; TISSUE FIXATION;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; OBSERVER VARIATION; QUALITY CONTROL; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 0344453811     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1354     Document Type: Review

References (72)

1. Slamon DJ, Clark GM, Wong SG. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
3. Reeves JR, Going JJ, Smith G, Cooke TG, Ozanne BW, Stanton PD. Quantitative radioimmunohistochemical measurements of p185(erbB-2) in frozen tissue sections. J Histochem Cytochem 1996; 44: 1251-1259.
4. Robertson KW, Reeves JR, Smith G, et al. Quantitative estimation of epidermal growth factor receptor and c-erb B-2 in human breast cancer. Cancer Res 1996; 56: 3823-3830.
5. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16: 413-428.
6. Andrulis IL, Bull SB, Blackstein ME, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998; 16: 1340-1349.
7. Dalifard I, Daver A, Goussard J, et al. p185 overexpression in 220 samples of breast cancer undergoing primary surgery: comparison with c-erbB-2 gene amplification. Bioorg Med Chem Lett 1998; 1: 855-861.
8. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15: 2894-2904.
9. Jukkola A, Bloigu R, Soini Y, Savolainen ER, Holli K, Blanco G. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer 2001; 37: 347-354.
10. Agrup M, Stal O, Olsen K, Wingren S. C-erbB-2 overexpression and survival in early onset breast cancer. Breast Cancer Res Treat 2000; 63: 23-29.
11. Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 2000; 27: 46-52.
12. Menard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000; 182: 150-162.
13. Cooke T, Reeves J, Lannigan A, Stanton P. The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. Eur J Cancer 2001; 37(suppl 1): S3-S10.
14. Piffanelli A, Dittadi R, Catozzi L, et al. Determination of ErbB2 protein in breast cancer tissues by different methods: relationships with other biological parameters. Breast Cancer Res Treat 1996; 37: 267-276.
15. Press MF. Oncogene amplification and expression: importance of methodologic considerations. Am J Clin Pathol 1990; 94: 240-241.
16. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54: 2771-2777.
17. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nature Rev Mol Cell Biol 2001; 2: 127-137.
18. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37: S3-S8.
19. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-212.
20. Carlomagno C, Perrone F, Gallo C, et al. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14: 2702-2708.
21. Paik S, Hartmann DP, Dickson RB, Lippman ME. Antiestrogen resistance in ER positive breast cancer cells. Breast Cancer Res Treat 1994; 31: 301-307.
22. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: 1361-1370.
23. Ravdin PM, Green S, Albain V, et al. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone. Proc Am Soc Clin Oncol 1998; 17: 97A.
24. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21: 309-318.
25. Giai M, Roagna R, Ponzone R, De Bortoli M, Dati C, Sismondi P. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 1994; 14: 1441-1450.
26. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma: a study of epidemiologic risk factors, histologic features, and prognosis. Cancer 1995; 75: 1320-1326.
27. Muss H, Berry D, Thor A, et al. Lack of interaction of tamoxifen (T) use and ErbB-2/Her-2/Neu (H) expression in CALGB 8541: a randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin and fluorouracil (CAF) in node TS1 positive primary breast cancer (BC). Proc Am Soc Clin Oncol 1999; 18: 68a.
28. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001; 28: 13-19.
29. Burris HA. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 2001; 28: 38-44.
30. Perez EA, Hortobagyi GN. Ongoing and planned adjuvant trials with trastuzumab. Semin Oncol 2000; 27: 26-32.
31. Ravdin PM. Should HER2 status be routinely measured for all breast cancer patients? Semin Oncol 1999; 26: 117-123.
32. Dowsett M, Cooke T, Ellis I, et al. Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 2001; 36: 170-176.
33. Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma: a detailed morphological analysis. J Pathol 1990; 161: 7-14.
34. Wittlinger T, Costa SD, Mietze M, Hendrik J, Kaufmann M, Bastert G. Immunohistochemical determination of c-erb b-2 (neu) oncogene product as prognostic parameter in breast-cancer. Arch Gynecol Obstet 1991; 250: 257-258.
35. Singleton TP, Niehans GA, Gu F, et al. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol 1992; 23: 1141-1150.
36. Kay EW, Walsh CJ, Cassidy M, Curran B, Leader M. C-erbB-2 immunostaining: problems with interpretation. J Clin Pathol 1994; 47: 816-822.
37. Pawlowski V, Revillion F, Hornez L, Peyrat JP. A real-time one-step reverse transcriptase-polymerase chain reaction method to quantify c-erbB-2 expression in human breast cancer. Cancer Detect Prev 2000; 24: 212-223.
38. Johnson RC, Ricci A, Cartun RW, Ackroyd R, Tsongalis GJ. p185(HER2) overexpression in human breast cancer using molecular and immunohistochemical methods. Cancer Invest 2000; 18: 336-342.
39. Wasserman LM, Wallace A. Detection of circulating tumor cells in breast cancer patients: preliminary validation of a semi-nested RT-PCR assay for HER2/neu. Am J Pathol 1998; 153: ST20.
40. Lyon E, Millson A, Lowery MC, Woods R, Wittwer CT. Quantification of HER2/neu gene amplification by competitive PCR using fluorescent melting curve analysis. Clin Chem 2001; 47: 844-851.
41. Jennings BA, Hadfield JE, Worsley SD, Girling A, Willis G. A differential PCR assay for the detection of c-erbB 2 amplification used in a prospective study of breast cancer. Mol Pathol 1997; 50: 254-256.
42. O'Malley FP, Parkes R, Latta E, et al. Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol 2001; 115: 504-511.
43. Nelson NJ. Experts debate value of HER2 testing methods. J Natl Cancer Inst 2000; 92: 292-294.
44. Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A, Marks A. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. Mod Pathol 2001; 14: 677-685.
45. Ellis IO, Dowsett M, Bartlett J, et al. Recommendations for HER2 testing in the UK. J Clin Pathol 2000; 53: 890-892.
46. Diaz NM. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy. Cancer Control 2001; 8: 415-418.
47. Lebeau A, Deimling D, Kaltz C, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001; 19: 354-363.
48. Kakar S, Puangsuvan N, Stevens JM, et al. Comparison of PathVysion and INFORM fluorescence in situ hybridization kits for assessment of HER-2/neu stares in breast carcinoma. Mol Diagn 2000; 5: 193-197.
49. Pauletti G, Dandekar S, Rong HM, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18: 3651-3664.
50. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000; 53: 374-381.
51. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999; 17: 1974-1982.
52. Bartlett JMS, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001; 195: 422-428.
53. Reeves JR, Cooke TG, Fenton-Lee D, et al. Localization of EGF receptors in frozen tissue sections by antibody and biotinylated EGF-based techniques. J Histochem Cytochem 1994; 42: 307-314.
54. Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002; 20: 3095-3105.
55. Penault Llorca F, Adelaide J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier J. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol 1994; 173: 65-75.
56. Going JJ, Mallon L, Reeves JR, et al. Inter-observer agreement in assessing c-erbB-2 status in breast cancer: immunohistochemistry and FISH. J Pathol 2000; 190: 19A.
57. Van Diest PJ, van Dam P, Henzen-Logmans SC, et al. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. Clin Pathol 1997; 50: 801-804.
58. Helin HJ, Helle MJ, Kallioniemi OP, Isola JJ. Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma: correlation with histopathology and DNA flow cytometry. Cancer 1989; 63: 1761-1767.
59. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in Q5 breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168.
60. Watters AD, Ballantyne SA, Going JJ, Grigor KM, Bartlett JMS. Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder. Br J Urol Int 2000; 85: 42-47.
61. Bartlett JMS, Adie L, Watters AD, Going JJ, Grigor KM. Chromosomal aberrations in transitional cell carcinoma that are predictive of disease outcome are independent of polyploidy. B J Urol Int 1999; 84: 775-779.
62. Bartlett JMS, Watters AD, Ballantyne SA, Going JJ, Grigor KM, Cooke TG. Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? Br J Cancer 1998; 77: 2193-2198.
63. Mass RD, Sanders C, Charlene K, Johnson L, Everett T, Anderson S. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials [Abstract 291]. Proc ASCO 2000; 19: 75a.
64. Mass RD, Press M, Anderson S, Murphy M, Slamon D. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridisation (FISH) [Abstract 85]. Proc. ASCO 2001; 20: 22a.
65. Vogel CL, Cobleigh M, Tripathy D, et al. Superior outcomes with Herceptin (trastuzumab) (H) in fluorescence in situ hybridisation (FISH)-selected patients [Abstract 86]. Proc ASCO 2001; 20: 22a.
66. Seidman AD, Fornier MN, Esteva MJ, et al. Weekly trastuzumab and paclitaxel therapy for metastic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19: 2587-2595.
67. Fornier M, Risio M, Van Poznak C, Seidman A. HER2 testing and correlation with efficacy of Trastuzumab therapy. Oncology - New York 2002; 16: 1340-1342.
68. Mitchell MS, Press MF. The role of immunohistochemistry and fluorescence in situ hybridization for HER-2/neu in assessing the prognosis of breast cancer. Semin Oncol 1999; 26: 108-116.
69. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002; 94: 852-854.
70. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast inter-group trial N9831. J Natl Cancer Inst 2002; 94: 855-857.
71. Paik S, Tan-Chiu E, Bryant J, et al. Successful quality assurance program for HER2 testing in the NSABP trial for Herceptin. Proceedings of the 25th Annual San Antonio Breast Cancer Symposium. Breast Cancer Research and Treatment 2002; 76: Suppl. 1, Abstract 9.
72. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridisation (FISH) for HER2 in 426 breast carcinomas from 37 centres. J Pathol 2003; 199: 418-423.